In this first episode of the new series, Executive Director of the Chacruna Institute Bia Labate, PhD, and Kelan Thomas, PharmD, MS, associate professor of clinical sciences at the Touro University California College of Pharmacy, discussed the global psychedelic medicine market.
Payton Nyquvest, CEO and founder of Numinus, discussed the laboratory development and regulatory side of psychedelic research.
Colonel Dallas Hack discussed the development of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder
Sexual health is directly linked to mental health, Ramsden said, and both issues often go under-investigated in women.
Kelsey Ramsden, co-founder, president, and CEO at MindCure, discussed the potential links between sexual trauma and hypoactive sexual desire disorder in women.
Kelan Thomas, PharmD, MS, discussed potential adverse effects and drug-drug interactions that pharmacists should be aware of with psychedelic medicines.
We spoke with Agnieszka Sekula and Prash Puspanathan, MD, co-founders of Enosis Therapeutics, about the use of virtual reality in psychedelic-assisted therapy.
Jim Gilligan, PhD, discusses a phase 2 study investigating psilocybin-assisted therapy for binge eating disorder.
This month, we spoke with Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, about ketamine and the future of the opioid epidemic.
For patients facing end-of-life care, psychedelic medicines may offer a chance to feel connected with themselves and others during such a difficult time.
Joseph Araujo, Chief Scientific Officer at Mindset Pharma, sat down to discuss natural vs. synthetic psychedelics.
This month, we spoke with expert Adi Zuloff-Shani, PhD, CEO of Clearmind Medicine.
Rick Strassman, MD, a clinical researcher, author, and expert in psychedelic medicines, sat down to discuss pharmacists' role in adverse event management.
David Keene, vice president of Digital Therapeutics at atai Life Sciences, discussed the growth and future of digital therapeutics.
Although it has some daunting adverse effects, Glenn Short, PhD, said ibogaine offers unique biological and therapeutic effects.
